HeartBeam has submitted a 510 (k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram ...

The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five ...

SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a $56.5 million market cap pioneer in medical technology currently trading at $2.12 per share, has announced the submission of a 510(k) ...

HeartBeam (NASDAQ: BEAT) , a medical technology company advancing cardiac care, has submitted a 510 (k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram ( ...

Medical technology company HeartBeam has secured two new patents from the US Patent and Trademark Office on its core vector electrocardiography (VECG) technology. HeartBeam’s VECG technology ...

rose sharply in today’s pre-market trading after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion Heartbeam shares are trading higher by 3 ...

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia assessment The Company is gearing up for an Early Access Program to gain initial ...

Heartbeam Inc. received U.S. FDA 510(K) clearance for its portable, non-invasive electrocardiogram system that enables on-the-go recording of heart signals. The cable-free, credit card-sized device ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

HeartBeam (NASDAQ: BEAT), a medical technology company revolutionizing cardiac care, announced its participation in the JP Morgan 2025 Annual Healthcare Conference, set for Jan. 13-16, 2025 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2025 ...